| Drug Type Recombinant protein | 
| Synonyms Recombinant viral protein R (VGX Pharmaceuticals), VGX 750 | 
| Target | 
| Action inhibitors | 
| Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePendingPreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Inflammation | Preclinical | United States  | - | |
| Sepsis | Discovery | United States  | 21 Aug 2005 | 






